Inositec AG is a biotech spin-off from ETH Zurich. The Company was founded in December 2015 to develop innovative new drugs using its proprietary technology Inositune™ to adjust the properties of inositol phosphate analogs. Initially, Inositec will focus on two areas of high-unmet medical need: calcification disorders and Clostridium difficile infection (CDI).
Founder and CEO: Mattias Ivarsson
Please click here for clinical trial information.